Clinical Trials

52 enrolled

Prostatic Neoplasms

NCT04393350 2026-04-20

Perioperative Lenvatinib With Pembrolizumab in Patients With Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

18 enrolled 12 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05766371 2026-04-17

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

48 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT03435952 2026-04-16

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

18 enrolled

BreastGenitourinary

Breast Neoplasms, Urologic Neoplasms

NCT07223424 2026-04-16

PSI-Immune

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

880 enrolled

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT05969496 2026-04-13

NEOPAX

17 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms

NCT05406713 2026-04-08

Pembrolizumab in Muscle-invasive Bladder Cancer

46 enrolled

Carcinoma, Transitional Cell

NCT02964078 2026-04-02

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

Phase 2 Completed

27 enrolled 10 charts

Phase EARLY_PHASE1 Recruiting

Kidney Diseases, Kidney Neoplasms, Neoplasm Metastasis

NCT05733715 2026-03-24

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

30 enrolled

Carcinoma, Renal Cell

NCT02690558 2026-03-20

Phase 2 Study of Pembrolizumab in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy

Phase 2 Completed

39 enrolled 16 charts

Phase 3 Active not recruiting

Urinary Bladder Neoplasms

NCT04637594 2026-03-20

IMAGINE

3 enrolled 6 charts

Carcinoma, Transitional Cell

NCT05923190 2026-03-19

Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma

60 enrolled

Carcinoma, Transitional Cell

NCT07027124 2026-03-19

Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer

40 enrolled

Phase 1 Active not recruiting

Prostatic Neoplasms

NCT04007744 2026-03-18

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors

36 enrolled

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Lung Neoplasms, Melanoma, Neoplasm Metastasis

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Carcinoma, Transitional Cell

NCT05843448 2026-03-13

IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer

Phase 1 Recruiting

30 enrolled

DermatologicGastrointestinalGenitourinaryGynecologic

Urinary Bladder Neoplasms

NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Phase 1 Completed

62 enrolled 17 charts

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

NCT05269381 2026-03-12

PNeoVCA

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

132 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07460206 2026-03-10

PRELUDE

Phase 2 Not yet recruiting

108 enrolled

Carcinoma, Renal Cell

NCT06860386 2026-03-06

Study of Adaptive Immunotherapy With VEGFR-TKI in Patients With Advanced RCC

Phase 2 Suspended

75 enrolled

Carcinoma, Renal Cell

NCT06809140 2026-02-23

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

47 enrolled

Muscle Invasive Bladder Urothelial Carcinoma

NCT04848519 2026-02-19

Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma

6 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms

NCT07221942 2026-02-19

IMPROEV

97 enrolled

Carcinoma, Transitional Cell

NCT06470282 2026-02-18

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

47 enrolled

Urinary Bladder Neoplasms

NCT07410676 2026-02-18

EBNK-ST-001

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicOther hematologic neoplasmSarcomaThoracic

83 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Bronchogenic, Disease, Esophageal Neoplasms, Glioblastoma, Kidney Neoplasms, Leukemia, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms

NCT06764095 2026-02-12

Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial

Phase 4 Recruiting

75 enrolled

Urinary Bladder Neoplasms, Ureteral Neoplasms

NCT05775471 2026-02-05

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

21 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma

NCT07183319 2026-02-02

Circulating Tumor DNA Response In Urothelial Cancer

30 enrolled

Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT05568550 2026-01-30

Pembro With Radiation With or Without Olaparib

64 enrolled

Prostatic Neoplasms

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

CNSEndocrineGenitourinary

157 enrolled 26 charts

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

Phase 1/2 Active not recruiting

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04856189 2026-01-29

Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma

Phase 1/2 Terminated

4 enrolled 8 charts

Phase 1 Active not recruiting

Carcinoma, Transitional Cell

NCT02432963 2026-01-28

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

11 enrolled

BreastDermatologicGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Carcinoma, Hepatocellular, Melanoma, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Triple Negative Breast Neoplasms

NCT04701918 2026-01-22

Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma

Phase 2 Completed

9 enrolled

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT07346053 2026-01-16

Chrono-EVP

224 enrolled

Advanced Bladder Cancer

NCT05656235 2026-01-08

Renal Retention in High Grade Upper Tract Urothelial Cancer

20 enrolled

Urinary Bladder Neoplasms

NCT07187778 2026-01-05

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

10 enrolled